Understanding molecular mechanisms of response and resistance to anticancer therapies requires prospective patient follow-up and clinical and functional validation of both common and low-frequency mutations. We describe a whole-exome sequencing (WES) precision medicine trial focused on patients with advanced cancer.
Whole-Exome Sequencing of Metastatic Cancer and Biomarkers of Treatment Response / Beltran, H; Eng, K; Mosquera, Jm; Sigaras, A; Romanel, Alessandro; Rennert, H; Kossai, M; Pauli, C; Faltas, B; Fontugne, J; Park, K; Banfelder, J; Prandi, Davide; Madhukar, N; Zhang, T; Padilla, J; Greco, N; Mcnary, Tj; Herrscher, E; Wilkes, D; Macdonald, Ty; Xue, H; Vacic, V; Emde, Ak; Oschwald, D; Tan, Ay; Chen, Z; Collins, C; Gleave, Me; Wang, Y; Chakravarty, D; Schiffman, M; Kim, R; Campagne, F; Robinson, Bd; Nanus, Dm; Tagawa, St; Xiang, Jz; Smogorzewska, A; Demichelis, Francesca; Rickman, Ds; Sboner, A; Elemento, O; Rubin, M. a.. - In: JAMA ONCOLOGY. - ISSN 2374-2437. - 1:4(2015), p. 466-74. [10.1001/jamaoncol.2015.1313]
Whole-Exome Sequencing of Metastatic Cancer and Biomarkers of Treatment Response
Romanel, Alessandro;Prandi, Davide;Demichelis, Francesca;
2015-01-01
Abstract
Understanding molecular mechanisms of response and resistance to anticancer therapies requires prospective patient follow-up and clinical and functional validation of both common and low-frequency mutations. We describe a whole-exome sequencing (WES) precision medicine trial focused on patients with advanced cancer.| File | Dimensione | Formato | |
|---|---|---|---|
|
Demichelis-Whole-coi150029.pdf
Solo gestori archivio
Tipologia:
Versione editoriale (Publisher’s layout)
Licenza:
Tutti i diritti riservati (All rights reserved)
Dimensione
750.68 kB
Formato
Adobe PDF
|
750.68 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione
